Company Description
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally.
The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.
It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases.
The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema.
Pharming Group N.V. is headquartered in Leiden, the Netherlands.
| Country | NL |
| IPO Date | Dec 23, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 382 |
| CEO | Dr. Sijmen de Vries M.B.A., M.D. |
Contact Details
Address: Darwinweg 24 Leiden, NL | |
| Website | https://www.pharming.com |
Stock Details
| Ticker Symbol | PHAR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001828316 |
| CUSIP Number | 71716E105 |
| ISIN Number | US71716E1055 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sijmen de Vries M.B.A., M.D. | President, Chief Executive Officer & Executive Director |
| Ines Bernal | Chief People Officer |
| Jeroen Wakkerman | Chief Financial Officer |
| Dr. Alexander Breidenbach M.B.A. | Chief Business Officer |
| Dr. Anurag Relan M.D., MPH | Chief Medical Officer |
| Dr. Bruno M. L. Giannetti | Consultant |
| Mireille Sanders M.Sc. | Chief Operations Officer |
| Ruud Van Outersterp | Chief Ethics & Compliance Officer |
| Stephen Toor | Chief Commercial Officer & GM Americas |
| Susanne Embleton | Investor Relations Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 6-K | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 24, 2024 | 6-K | Filing |
| Oct 10, 2024 | 6-K | Filing |
| Sep 26, 2024 | 6-K | Filing |
| Aug 01, 2024 | 6-K | Filing |
| May 30, 2024 | 6-K | Filing |
| May 21, 2024 | 6-K | Filing |
| May 15, 2024 | 6-K | Filing |